Melemedjian, Ohannes K <br/><br/>
Targeting adenosine monophosphate-activated protein kinase (AMPK) in preclinical models reveals a potential mechanism for the treatment of neuropathic pain.  [electronic resource] 

 -  Molecular pain  Sep 2011 
 - 70 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1744-8069 
<br/><br/><label>Standard No.: </label>10.1186/1744-8069-7-70  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>AMP-Activated Protein Kinase Kinases<br/>Action Potentials--drug effects<br/>Animals<br/>Blotting, Western<br/>Disease Models, Animal<br/>Enzyme Activators--pharmacology<br/>Eukaryotic Initiation Factor-4F--biosynthesis<br/>Hyperalgesia--complications<br/>Male<br/>Mice<br/>Mice, Inbred ICR<br/>Molecular Targeted Therapy<br/>Neuralgia--drug therapy<br/>Protein Biosynthesis--drug effects<br/>Protein Kinases--metabolism<br/>Rats<br/>Rats, Sprague-Dawley<br/>Sciatic Nerve--drug effects<br/>Sensory Receptor Cells--drug effects<br/>Signal Transduction--drug effects